Industry: Therapeutics for diseases of the cornea
Founded by four blood industry experts from Emory University, Cambium Medical Technologies develops regenerative therapies derived from human platelets.
The company’s novel process for producing standardized platelets has various therapeutic applications. Cambium has also partnered with Zheng Yang Biomedical Technology in Taiwan to commercialize its platelets as a stem cell growth supplement.
Cambium’s leading candidate for clinical development is a pharmaceutical treatment for dry eye syndrome (keratoconjuctivitis sicca), along with other corneal diseases. Branded as Elate Ocular™, the treatment is a topical eye drop derived from human platelets.
Dry eye affects around 25 million people in the U.S. and is one of the fastest growing pharmaceutical needs in the ophthalmology market. The worldwide market for dry eye pharmaceuticals is projected to grow to $3 billion by 2018.
Company website: Cambium Technologies